IP Library Granted Patent US 7,479,372
Granted Patent B2
US 7,479,372 · App. 11/523,507 · Granted Jan 20, 2009

Beta-secretase substrates and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,479,372
App. No.
11/523,507
Granted
Jan 20, 2009
Kind
B2
Abstract

The present invention provides synthetic β-secretase peptide substrates useful in various assays for measuring β-secretase activity. Antibodies that recognize the synthetic substrates and uses of the antibodies in various assays are disclosed. The herein disclosed peptide substrates are hydrolyzed at rates substantially faster than the attendant Swedish mutant APP from which the substrate sequences are derived.

Claims (21)

1. A method for assaying for decreased β-secretase activity comprising measuring a cleavage product produced from cleavage by β-secretase of β-amyloid precursor protein (APP) substrate comprising a β-secretase peptide substrate, comprising a β-secretase cleavage site and having the formula P4-P3-P2-P1-P1′-P2′-P3′-P4′, where

P4 is selected from the group consisting of D, E, I, L and V;

P3 is selected from the group consisting of L, I, V and N;

P2 is selected from the group consisting of F, Y, E and N;

P1 is selected from the group consisting of F, I, L and Y;

P1′ is selected from the group consisting of A, E, S, I, L and D;

P2′ is selected from the group consisting of V, I, L and A;

P3′ is selected from the group consisting of V, I, L, E and Y; and

P4′ is selected from the group consisting of P, W and F;

where P4-P3-P2-P1-P1′-P2′-P3′-P4′ cannot simultaneously be chosen such that they comprise the Swedish mutation β-secretase cleavage site (SEQ ID NO: 257); and

where a decrease in β-secretase activity is determined when the amount of the cleavage product is decreased relative to the amount of the cleavage product produced from an APP substrate having the Swedish mutation β-secretase cleavage site (SEQ ID No: 257).

2. The method of claim 1 wherein said β-secretase peptide substrate corresponds to positions 593-600 of APP695.

3. The method of claim 2 wherein said β-secretase peptide substrate comprises SEQ ID NO: 262.

4. The method of claim 1 wherein the β-secretase activity is measured using an antibody that binds to the carboxyl terminus of the cleaved APP substrate.

5. The method of claim 1 wherein the cleavage product detected is the C-terminal cleavage product of said APP substrate.

6. The method of claim 1 for assaying for decreased β-secretase activity in the presence of one or more test compounds, where the decreased β-secretase activity is determined when the amount of the cleavage product is decreased relative to the amount of the cleavage product produced from an APP substrate having a β-secretase peptide substrate of the Swedish mutationβ-secretase cleavage site (SEQ ID NO: 257) in the absence of said compounds.

7. The method of claim 6 wherein the decreased β-secretase activity in the presence of one or more test compounds is indicative that said compounds inhibit β-secretase activity.

8. The method of claim 6 wherein said β-secretase peptide substrate corresponds to positions 593-600 of APP695.

9. The method of claim 6 wherein said β-secretase substrate comprises SEQ ID NO: 262.

10. The method of claim 6 wherein the β-secretase activity is measured using an antibody that binds to the carboxyl terminus of the cleaved APP substrate.

11. The method of claim 1 wherein the cleavage product detected is C-terminal cleavage product of said APP substrate.

Assignments (1)
CHANGE OF NAME Recorded Jan 29, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023870/0001 →